Safety and effectiveness of autologous leukocyte-rich platelet-rich plasma therapy (L-PRP therapy) for damage, deficit and prolonged healing in the musculoskeletal system of the human body

Safety and effectiveness of autologous leukocyte-rich platelet-rich plasma therapy (L-PRP therapy) for damage, deficit and prolonged healing in the musculoskeletal system of the human body - Safety and effectiveness of autologous leukocyte-rich platelet-rich plasma therapy (L-PRP therapy)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032134

Enrollment

Registered

2018-04-06

Start date

2018-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intractable muscle of damaged tendon attachment and muscle tendon transitiontendonitis, humeral superior condylitis, elbow medial collateral ligament injury, knee medial collateral ligament injury

Interventions

Self-High Leukocyte Platelet Rich Plasma Therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with target disease Patients who got consent in writing from the person or the substitute Patients without bacterial infection Age is over 20 years old, gender does not matter

Exclusion criteria

Exclusion criteria: Patients with bacterial infections in the whole body or in areas undergoing this treatment Patients who are suggestive of the possibility of affecting the general condition when infection is caused by this therapy Patients who have a fever of 37 degrees or more without using antipyretics or anti-inflammatory analgesics Patients with open wounds Patients during oral treatment

Design outcomes

Primary

Measure	Time frame
Self and other senses Clinical laboratory test (blood test Physical findings Visual Analog Scale Sports Reversion Scale	—

Countries

Japan

Contacts

Public ContactRei Tsuruga

Jikei University Orthopedic

tsuruga1021@gmail.com08054861238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026